The pipeline is advancing with late-stage studies for plozasiran and zodasiran, targeting severe hypertriglyceridemia and HoFH, respectively, and a dual-functional siRNA for mixed hyperlipidemia. Long-term data show robust efficacy and safety, with key data readouts and potential launches expected in 2026-2027.
Based on
This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.